Lukang Pharmaceutical subsidiary Montmorillonite scattered reviews

Release date: 2020-01-14 Views: 0

Source: Sina Medical News  

Recently, Lukang Pharmaceutical subsidiary Sete received the “Approval for Supplementary Drug Application” for Montmorillonite issued by the State Drug Administration (approval number: 2020B02000). Montmorillonite passed the consistency evaluation of the quality and efficacy of generic drugs .

It is reported that montmorillonite powder is the recommended medication for clinical guidelines for infectious diarrhea in China. At present, montmorillonite powder is mainly used for the adjuvant treatment of acute and chronic diarrhea, esophagus, stomach and duodenal disease related pain symptoms in adults and children.

The market prospect of montmorillonite is broad. From January to September 2019, the sales of the drug in domestic medical institution terminals and retail terminals were about 700 million yuan, and the sales revenue of this product by Scitech was 2.173 million yuan.

It is worth mentioning that there are currently 39 production approvals for montmorillonite in China. As of the date of this announcement, a total of 13 companies including Sichuan Weiao Pharmaceutical Co., Ltd., Yangzijiang Pharmaceutical Group Co., Ltd., and Shandong Lukang Pharmaceutical Group Sete Co., Ltd. have passed the consistent evaluation and approval of the State Drug Administration.

Source: Listed company announcement

latest articles

recommended article

Hunter QR code